Skip to main content
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. — Investor Relations & Filings

Ticker · JBIO ISIN · US0080641071 US Professional, scientific and technical activities
Open in API
Filings indexed 461 across all filing types
Latest filing 2026-06-04 Capital/Financing Update
Country US United States of America
Listing US JBIO

About Jade Biosciences, Inc.

https://jadebiosciences.com/

Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, inflammation, and immunology. The company aims to create transformative, disease-modifying treatments to address significant unmet medical needs and redefine the standard of care. Its pipeline features novel biologics, with the lead candidate, JADE101, being developed for the treatment of immunoglobulin A nephropathy (IgAN). JADE101 is an inhibitor of the cytokine APRIL (A PRoliferation-Inducing Ligand). The company's programs are based on discovery-stage assets licensed from Paragon Therapeutics.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 87% confidence The document is an SEC Form 8-K (a current report) describing the company’s entry into an underwriting agreement for the issuance and sale of 10,000,000 common shares, details of the offering price, underwriters’ option, expected proceeds, and closing conditions. This is clearly an update on the company’s financing activity (equity offering). According to the filing definitions, updates on company fundraising, financing activities, or capital structure changes fall under Capital/Financing Update (CAP).
2026-06-04 English
424B5
Capital/Financing Update Classification · 85% confidence The document is an SEC Form 424B5 prospectus supplement filed under Rule 424(b)(5) describing a new equity offering of 10,000,000 shares of common stock, with detailed terms, risk factors, underwriting information, use of proceeds, etc. This is a capital raising document relating to financing activities rather than a periodic report, management discussion, or legal proceeding. It therefore falls under the Capital/Financing Update category.
2026-06-04 English
424B5
Capital/Financing Update Classification · 87% confidence The document is a preliminary prospectus supplement (Form 424(b)(5)) and accompanying prospectus relating to the offering of common stock and pre-funded warrants. It contains detailed terms of the offering, use of proceeds, underwriting arrangements, risk factors, dilution tables, and registered securities pricing. This is a formal capital raising document under SEC registration, not an earnings report, management discussion, or certificate. It falls squarely into the Capital/Financing Update category, which covers fundraising and financing activities.
2026-06-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, containing Regulation FD disclosure of a corporate slide presentation and interim Phase 1 clinical trial results. It is not an earnings release of financial results, not a proxy/material solicitation, nor an actual investor slide deck distributed outside the 8-K. The document itself is a regulatory filing that does not fit any more specific category, so it defaults to the miscellaneous Regulatory Filings category (RNS).
2026-06-01 English
424B3
Regulatory Filings Classification · 80% confidence The document is a Securities Act prospectus (Rule 424(b)(3)) for resale of registered shares by selling stockholders. It is not a financial report (10-K, IR), not an earnings release, not a management discussion, not a proxy statement, etc. It is a compliance filing with the SEC to register shares for resale, which best fits the “Regulatory Filings (RNS)” category as a general regulatory/compliance document.
2026-05-15 English
S-8 - Jade Biosciences, Inc. (0001798749) (Filer)
Regulatory Filings Classification · 85% confidence The document is a full SEC Form S-8 registration statement for Jade Biosciences to register shares under an employee inducement stock incentive plan. It is not an annual or quarterly report, earnings release, proxy, dividend notice, management/change announcement, or any of the other specific categories. It’s a regulatory form filing with the SEC, so it falls under the fallback category “Regulatory Filings (RNS).”
2026-05-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.